Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 23 (12), 1113-1126

Near-infrared Fluorescence Imaging for Sentinel Lymph Node Identification in Colon Cancer: A Prospective Single-Center Study and Systematic Review With Meta-Analysis


Near-infrared Fluorescence Imaging for Sentinel Lymph Node Identification in Colon Cancer: A Prospective Single-Center Study and Systematic Review With Meta-Analysis

M Ankersmit et al. Tech Coloproctol.


Background: Near-infrared (NIR) fluorescence imaging has the potential to overcome the current drawbacks of sentinel lymph node mapping (SLNM) in colon cancer. Our aim was to provide an overview of current SLNM performance and of factors influencing successful sentinel lymph node (SLN) identification using NIR fluorescence imaging in colon cancer.

Methods: A systematic review and meta-analysis was conducted to identify currently used methods and results. Additionally, we performed a single-center study using indocyanine green (ICG) as SLNM dye in colon cancer patients scheduled for a laparoscopic colectomy. SLNs were analyzed with conventional hematoxylin-and-eosin staining and additionally with serial sectioning and immunohistochemistry (extended histopathological assessment). A true-positive procedure was defined as a tumor-positive SLN either by conventional hematoxylin-and-eosin staining or by extended histopathological assessment, independently of regional lymph node status. SLN procedures were determined to be true negatives if SLNs and regional lymph nodes revealed no metastases after conventional and advanced histopathology. SLN procedures yielding tumor-negative SLNs in combination with tumor-positive regional lymph nodes were classified as false negatives. Sensitivity, negative predictive value and detection rate were calculated.

Results: This systematic review and meta-analysis included 8 studies describing 227 SLN procedures. A pooled sensitivity of 0.63 (95% CI 0.51-0.74), negative predictive value 0.81 (95% CI 0.73-0.86) and detection rate of 0.94 (95% CI 0.85-0.97) were found. Upstaging as a result of extended histopathological assessment was 0.15 (95% CI 0.07-0.25). In our single-center study, we included 30 patients. Five false-negative SLNs were identified, resulting in a sensitivity of 44% and negative predictive value of 80%, with a detection rate of 89.7%. Eight patients had lymph node metastases, in three cases detected after extended pathological assessment, resulting in an upstaging of 13% (3 of 23 patients with negative nodes by conventional hematoxylin and eosin staining).

Conclusions: Several anatomical and technical difficulties make SLNM with NIR fluorescence imaging in colon cancer particularly challenging when compared to other types of cancer. As a consequence, reports of SLNM accuracy vary widely. Future studies should try to standardize the SLNM procedure and focus on early-stage colon tumors, validation of tracer composition, injection mode and improvement of real-time optical guidance.

Keywords: Colon cancer; IRDye800CW; Indocyanine green; Sentinel lymph node.

Conflict of interest statement

The authors declare that they have no conflict of interest.


Fig. 1
Fig. 1
Flow diagram of study selection
Fig. 2
Fig. 2
Pooled sensitivity
Fig. 3
Fig. 3
Pooled negative predicitive value
Fig. 4
Fig. 4
Pooled detection rate
Fig. 5
Fig. 5
Pooled upstaging

Similar articles

See all similar articles


    1. de Wijkerslooth TR, de Haan MC, Stoop EM, Deutekom M, Fockens P, Bossuyt PM, Thomeer M, van Ballegooijen M, Essink-Bot ML, van Leerdam ME, Kuipers EJ, Dekker E, Stoker J. Study protocol: population screening for colorectal cancer by colonoscopy or CT colonography: a randomized controlled trial. BMC Gastroenterol. 2010;10:47. doi: 10.1186/1471-230X-10-47. - DOI - PMC - PubMed
    1. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer I Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351. doi: 10.1056/nejmoa032709. - DOI - PubMed
    1. Cahill RA, Leroy J, Marescaux J. Localized resection for colon cancer. Surg Oncol. 2009;18(4):334–342. doi: 10.1016/j.suronc.2008.08.004. - DOI - PubMed
    1. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008 doi: 10.1002/14651858.CD005390.pub2. - DOI - PubMed
    1. Sloothaak DA, Sahami S, van der Zaag-Loonen HJ, van der Zaag ES, Tanis PJ, Bemelman WA, Buskens CJ. The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2014;40(3):263–269. doi: 10.1016/j.ejso.2013.12.002. - DOI - PubMed

LinkOut - more resources